初诊时附加染色体异常对接受一线酪氨酸激酶抑制剂治疗的慢性髓性白血病患者预后的意义
该研究分析了前瞻性临床试验中603例初诊慢性髓性白血病慢性期患者,其中29例(5%)存在附加染色体异常。接受一线酪氨酸激酶抑制剂治疗时,附加染色体异常组与无附加染色体异常组在6个月完全细胞遗传学缓解率上有显著差异(无附加染色体异常组更高,P=0.02),但累积完全细胞遗传学缓解率、主要分子学缓解率及5年生存结局无显著差异。作者认为初诊时附加染色体异常不应改变治疗策略。
要点
- 603例初诊慢性期慢性髓性白血病患者中,29例(5%)存在附加染色体异常。
- 6个月完全细胞遗传学缓解率在无附加染色体异常组显著更高(P=0.02),但累积缓解率无差异。
- 5年无转化生存、无失败生存、无事件生存及总生存均未受附加染色体异常显著影响。
核心结论
- 初诊时存在附加染色体异常并不给接受酪氨酸激酶抑制剂治疗的慢性髓性白血病患者带来更差预后,因此不应改变治疗策略。
研究设计与样本
- 分析前瞻性临床试验中接受一线酪氨酸激酶抑制剂治疗的初诊慢性期慢性髓性白血病患者,共603例,其中29例(5%)存在附加染色体异常。
主要发现
- 附加染色体异常患者分布:伊马替尼400 mg组2/72例(2.8%),伊马替尼800 mg组9/207例(4.3%),达沙替尼组10/148例(6.7%),尼洛替尼组6/126例(4.7%),帕纳替尼组2/50例(4%)。
- 6个月完全细胞遗传学缓解率在无附加染色体异常组显著更高(P=0.02)。
- 累积完全细胞遗传学缓解率和主要分子学缓解率在两组间无差异;MR4.0和MR4.5率两组相似,2例附加染色体异常患者维持MR4.5至少2年。
- 5年时,初诊附加染色体异常对无转化生存、无失败生存、无事件生存或总生存均无显著影响。
- 承认样本量小,附加染色体异常患者中无论染色体异常为「主要途径」或其他,缓解率和生存结局相当。
临床怎么用
- 作者认为初诊时存在附加染色体异常不应改变慢性髓性白血病患者的治疗策略。
局限性
- 样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Additional cytogenetic abnormalities (ACA) are considered a high risk feature in chronic myeloid leukemia (CML). However, its prognostic significance at the time of diagnosis in the setting of new tyrosine kinase inhibitors (TKIs) is less well understood. Patients with CML in CP with or without ACA at diagnosis treated with frontline TKIs in prospective clinical trials were analyzed for outcomes. Among 603 patients treated, 29 (5%) had ACA. Patients with ACA included 2 of 72 (2.8%) treated with imatinib 400 mg, 9 of 207 (4.3%) with imatinib 800 mg, 10 of 148 (6.7%) with dasatinib, 6 of 126 (4.7%) with nilotinib, and 2 of 50 (4%) with ponatinib. There was a significantly higher rate of complete cytogenetic response (CCyR) at 6 months in patients without ACA (P = .02). However cumulative CCyR and major molecular response (MMR) rates were not different. Similarly, MR4.0 and MR4.5 rates were similar for both groups; two CML-ACA patients maintained MR 4.5 for at least 2 years. At 5 years, ACA at diagnosis did not significantly impact transformation-free, failure-free, event-free, or overall survival expectations. Acknowledging small sample size estimates, response rates and survival outcomes were comparable in CP with ACA irrespective of whether chromosomal abnormalities were "major route" or other. The presence of ACA at diagnosis does not confer worse prognosis for patients with CML treated with TKI. Thus, the presence of ACA at diagnosis should not alter treatment strategies in these patients.
引用
- Alhuraiji A, Kantarjian H, Boddu P, et al. Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol. 2017. PMID: 29027261. doi:10.1002/ajh.24943
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。